Antoniou Dimosthenis, Kyprianou Kostas, Stathopoulos George P, Skarleas Christos, Kolitsi Georgia, Veslemes Marinos, Dimitroulis John, Giamboudakis Pantelis, Marosis Kostas, Armenaki Ourania, Papageorgiou C, Katis Costas
Hospital of Thoracic Diseases, Athens, Greece.
Oncol Rep. 2005 Sep;14(3):733-6.
The present study involves non-small cell lung (NSCLC) cancer patients with brain metastases, who were treated with radiation therapy, and our aim was to determine response rate and survival. A total of 167 patients were recruited, 155 (125 male, 30 female) of whom were evaluable. Performance status was 0-2 and histology or cytology included 66 (42.58%) adenocarcinomas, 62 (40.00%) undifferentiated and 27 (17.42%) squamous cell carcinomas. The stage of disease at diagnosis was IIIA-B in 92 (59.35%) patients and IV in 63 (40.65%). All patients had whole brain irradiation (3 Gy x 5 days/week for 2 weeks to a total dose of 30 Gy), which was performed by a linear accelerator and a 6-MV photon beam. Objective response was observed in 59/155 (38.06%) patients with 17 (10.97%) complete and 42 (27.09%) partial responses, and median survival of 5 months for all patients [95% confidence interval (CI) 3.9-6.1]. Responders had statistically significant longer survival than non-responders. Although responders represented less than half of our patients with NSCLC and brain metastases, they had significantly longer survival.
本研究纳入了接受放射治疗的非小细胞肺癌（NSCLC）脑转移患者，我们的目的是确定缓解率和生存率。共招募了167例患者，其中155例（125例男性，30例女性）可进行评估。体能状态为0 - 2，组织学或细胞学类型包括66例（42.58%）腺癌、62例（40.00%）未分化癌和27例（17.42%）鳞状细胞癌。诊断时疾病分期为IIIA - B期的患者有92例（59.35%），IV期的有63例（40.65%）。所有患者均接受全脑照射（3 Gy×每周5天，共2周，总剂量30 Gy），由直线加速器和6 - MV光子束进行。155例患者中有59例（38.06%）观察到客观缓解反应，其中17例（10.97%）完全缓解，42例（27.09%）部分缓解，所有患者的中位生存期为5个月[95%置信区间（CI）3.9 - 6.1]。缓解者的生存期在统计学上显著长于未缓解者。尽管缓解者在我们的NSCLC脑转移患者中不到一半，但他们的生存期明显更长。
